`
`Daniel R. Evans, Esq.
`
`MERCHANT & GOULD P.C.
`1900 Duke Street, Suite 600
`Alexandria, VA 22314
`Main Telephone: (703) 684-2500
`Main Facsimile: (703) 684-2501
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_____________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________________
`
`
`BRECKENRIDGE PHARMACEUTICAL, INC.
`Petitioner
`
`v.
`
`
`RESEARCH CORPORATION TECHNOLOGIES, INC.
`Patent Owner
`
`_____________________
`
`Case No. To Be Assigned
`Patent No. RE38,551
`_____________________
`
`
`APPENDIX OF EXHIBITS
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Exhibit Name
`Ex. #
`1001 U.S. Patent No. RE38,551 (“the '551 patent”)
`1002 Declaration of Dr. Binghe Wang
`1003 Declaration of Dr. Clayton Heathcock from IPR2014-01126
`1004 Joint Statement of Uncontested Facts
`1005 U.S. Patent No. 5,773,475 (“the '475 Patent”)
`1006 Excerpt from U.S. Patent Application No. 08/818,688
`1007 District Court Claim Construction Opinion
`1008 Philippe LeGall, 2-Substituted-2-acetamido-N-benzylacetamides.
`Synthesis, Spectroscopic and Anticonvulsant Properties (Dec. 1987)
`(“LeGall”)
`1009 U.S. Patent No. 5,378,729 (“the '729 Patent”)
`1010 Choi et al., Trimethylsilyl Halides: Effective Reagents for the Synthesis of
`β-Halo Amino Acid Derivatives, Tet. Lett., Vol. 36(39), pg. 7011 (1995)
`(“Choi 1995”)
`1011 Purdie et al., The Alkylation of Sugars, J.A.C.S.Vol. 83, pg. 1021 (1903)
`(“Purdie”)
`1012 Kohn et al., Preparation and Anticonvulsant Activity of a Series of
`Functionalized α-Heteroatom-Substituted Amino Acids, J. Med. Chem.
`Vol. 34, pg. 2444 (1991) (“Kohn 1991”)
`1013 Silverman, R. B., The Organic Chemistry of Drug Design and Drug
`Action, Academic Press (1992) (“Silverman”)
`1014 Development of New Stereoisomeric Drugs, U.S. F.D.A., May 1, 1992
`1015 Cortes et al., Effect of Structural Modification of the Hydantoin Ring on
`Anticonvulsant Activity, J. Med. Chem., Vol. 28, pg. 601 (1985)
`(“Cortes 1985”)
`1016 LeGall et al., Synthesis of Functionalized Non-Natural Amino Acid
`Derivatives via Amidoalkylation Transformations, Int. J. Peptide
`Protein Res. Vol. 32, pg. 279 (1988) (“LeGall 1988”)
`1017 Kohn et al., Synthesis and Anticonvulsant Activities of α-Heterocyclic α-
`Acetamido-N-benzylacetamide Derivatives, J. Med. Chem. Vol. 36, pg.
`3350 (1993)
`
`1
`
`
`
`
`
`
`
`
`1018 Kohn et al., Preparation and Anticonvulsant Activity of a Series of
`Functionalized α-Aromatic and α-Heteroaromatic Amino Acids, J. Med.
`Chem. Vol. 33, pg. 919 (1990)
`1019 U.S. Patent No. 5,654,301 (“the '301 Patent”)
`1020 Patent Term Extension Request in U.S. Patent No. 5,654,301
`1021 FDA Guideline for Industry, November 1994
`1022 Schmidt, R., Dose-Finding Studies in Clinical Drug Development, Eur. J.
`Clin. Pharmacol, Vol. 34, pg. 15 (1988)
`1023 Isbell, H. S., The Optical Rotation of the Various Asymmetric Carbon
`Atoms in the Hexose and Pentose Sugars, B. S. Jour. Research, Vol. 5, pg.
`1041 (1929)
`1024 Wilson and Gisvold’s Textbook of Organic Medicinal Chemistry,
`Physicochemical Properties in Relation to Biologic Action, (Delgado J.
`N. & Remers W. A., eds. 1991) (Wilson)
`1025 Thornber, C. W., Isosterism and Molecular Modification in Drug Design,
`Chem. Soc. Rev., Vol. 8(4) (1979)
`1026 Reissue Declaration in Reissue of U.S. Patent No. 5,773,475
`1027 Subpoena directed to The University of Houston
`1028 Texas Public Information Act Requests and Responses
`1029 Zhou et al., Decisions under Uncertainty: the Fuzzy Compromise
`Decision Support Problem, Eng. Opt. Vol. 20, pg. 21 (1992)
`1030 Mistree et al., A Decsion-Based Perspective for the Design of Methods
`for Systems Design, (1989)
`1031 Mistree et al., A Decision-based Approach to Concurrent Design,
`Concurrent Engineering: Contemporary Issues and Modern Design
`Tools, (Parsaei, H. R. & Sullivan W. G. Eds. 1993)
`1032 Ingram W. T., Concerning Periodic Points in Mappings of Continua, J.
`Am. Math. Soc., Vol. 104(2) (1988)
`1033 Mattson, Current Challenges in the Treatment of Epilepsy, Neurology,
`Vol. 44(suppl. 5), pg. 84 (1994)
`1034 Löscher et al., New Avenues for Anti-Epileptic Drug Discovery and
`Development, Nature Reviews: Drug Discovery, Vol. 12, pg. 12 (2013)
`
`2
`
`
`
`
`
`
`
`
`
`
`1035 Cohen authorized amendment in U.S. Patent Application No. 08/818,688
`
`
`
`
`
`3
`
`
`
`
`
`
`CERTIFICATION OF SERVICE
`
`The undersigned hereby certifies that this “APPENDIX OF EXHIBITS” was
`
`served in its entirety this 21st day of June, 2016 on the Patent Owner by serving
`
`via overnight delivery the correspondence address of record for the ’551 patent and
`
`also the Patent Owner:
`
`Covington & Burling, LLP
`Attn: Patent Docketing
`One CityCenter
`850 Tenth Street, NW
`Washington, DC 20001-4956
`
`Shaun A. Kirkpatrick,
`President, Biotechnologies
`Research Corporation Technologies
`5210 East Williams Circle, Suite 240
`Tucson, Arizona 85711-4410
`
`Courtesy copies of the foregoing were also served via email on counsel of
`
`record for the Petitioner and Patent Owner in Argentum Pharmaceuticals LLC v.
`
`Research Corporation Technologies, Inc., IPR2016-00204 as follows:
`
`Argentum Pharmaceuticals LLC
`
`
`Matthew J. Dowd
`Andrews Kurth LLP
`1350 I Street, NW, Suite 1100
`Washington, DC 20005
`MatthewDowd@andrewskurth.com
`
`Justin W. Crotty, Ph.D.
`Andrews Kurth LLP
`1350 I Street, NW, Suite 1100
`Washington, DC 20005
`
`
`
`4
`
`
`
`
`
`JustinCrotty@andrewskurth.com
`
`
`Research Corporation Technologies, Inc.
`
`
`Andrea G. Reister
`Covington & Burling LLP
`One CityCenter
`850 Tenth Street, NW
`Washington, DC 20001
`areister@cov.com
`
`Jennifer L. Robbins
`Covington & Burling LLP
`The New York Times Building
`620 Eighth Avenue
`New York, NY 10018
`jrobbins@cov.com
`
`Enrique D. Longton
`Covington & Burling LLP
`One CityCenter
`850 Tenth Street, NW
`Washington, DC 20001
`rlongton@cov.com
`
`Date: June 21, 2016
`
`
`
`
`
`/Matthew L. Fedowitz/
`Matthew L. Fedowitz, Esq., Reg. No. 61,386
`Daniel R. Evans, Esq., Reg. No. 55,868
`Merchant & Gould P.C.
`1900 Duke Street, Suite 600
`Alexandria, VA 22314
`mfedowitz@merchantgould.com
`devans@merchantgould.com
`Main Telephone: (703) 684-2500
`Main Facsimile: (703) 684-2501
`Counsel for Petitioner
`
`
`
`5
`
`